查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1243715

克拉伯病治療藥的全球市場

Krabbe Disease Treatment
出版日期: | 出版商: Global Industry Analysts, Inc. | 英文 194 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

克拉伯病治療藥的全球市場2030年前將達到19億美元

在COVID-19後改變的商務環境中，2022年12億美元的克拉伯病治療藥的全球市場，2030年前將達到19億美元的規模，在2022年～2030年預計將以年複合成長率6.2％增長。本報告所分析之市場區隔之一的抗痙攣劑年複合成長率將記錄5.3％，到分析期間結束時將達到7億4,570萬美元。考慮疫情後的復甦，肌肉鬆弛劑領域今後8年的年複合成長率將修正為5.9％。

美國市場估算為3億6,060萬美元，中國則將以年複合成長率5.9％增長

美國的克拉伯病治療藥市場在2022年估算為3億6,060萬美元。作為世界第2大經濟大國的中國，在2022年～2030年年複合成長率預計將為5.9％，2030年前將達到3億4,060萬美元的市場規模。其他熱門的地區市場有日本和加拿大，在2022年～2030年預計將各以5.7％和5.1％的速度成長。在歐洲市場中，德國以年複合成長率約5.1％成長。

調查對像企業範例

  • Abbott Laboratories
  • CENETOGENE N.V.
  • GlaxoSmithKline
  • Johnson & Johnson
  • Novartis AG
  • Pfizer
  • Sanofi-Aventis SA
  • Shire
  • Teva Pharmaceutical Industries Ltd.
  • UCB Pharmaceuticals

目錄

第1章 調查手法

第2章 摘要整理

  • 市場概要
  • 主要企業
  • 市場趨勢與推動因素
  • 全球市場預測

第3章 市場分析

  • 美國
  • 加拿大
  • 日本
  • 中國
  • 歐洲
  • 法國
  • 德國
  • 義大利
  • 英國
  • 其他歐洲
  • 亞太地區
  • 全球其他地區

第4章 競爭

簡介目錄
Product Code: MCP12910

What`s New for 2023?

»Special coverage on Russia-Ukraine war; global inflation; easing of "zero-Covid" policy in China and its `bumpy` reopening; supply chain disruptions, global trade tensions; and risk of recession.

»Global competitiveness and key competitor percentage market shares

» Market presence across multiple geographies - Strong/Active/Niche/Trivial

»Online interactive peer-to-peer collaborative bespoke updates

»Access to our digital archives and MarketGlass Research Platform

»Complimentary updates for one year

Looking Ahead to 2023

The global economy is at a critical crossroads with a number of interlocking challenges and crises running in parallel. The uncertainty around how Russia`s war on Ukraine will play out this year and the war`s role in creating global instability means that the trouble on the inflation front is not over yet. Food and fuel inflation will remain a persistent economic problem. Higher retail inflation will impact consumer confidence and spending. As governments combat inflation by raising interest rates, new job creation will slowdown and impact economic activity and growth. Lower capital expenditure is in the offing as companies go slow on investments, held back by inflation worries and weaker demand. With slower growth and high inflation, developed markets seem primed to enter into a recession. Fears of new COVID outbreaks and China's already uncertain post-pandemic path poses a real risk of the world experiencing more acute supply chain pain and manufacturing disruptions this year. Volatile financial markets, growing trade tensions, stricter regulatory environment and pressure to mainstream climate change into economic decisions will compound the complexity of challenges faced. Year 2023 is expected to be tough year for most markets, investors and consumers. Nevertheless, there is always opportunity for businesses and their leaders who can chart a path forward with resilience and adaptability.

Global Krabbe Disease Treatment Market to Reach $1.9 Billion by 2030

In the changed post COVID-19 business landscape, the global market for Krabbe Disease Treatment estimated at US$1.2 Billion in the year 2022, is projected to reach a revised size of US$1.9 Billion by 2030, growing at aCAGR of 6.2% over the period 2022-2030. Anticonvulsants, one of the segments analyzed in the report, is projected to record 5.3% CAGR and reach US$745.7 Million by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Muscle Relaxants segment is readjusted to a revised 5.9% CAGR for the next 8-year period.

The U.S. Market is Estimated at $360.6 Million, While China is Forecast to Grow at 5.9% CAGR

The Krabbe Disease Treatment market in the U.S. is estimated at US$360.6 Million in the year 2022. China, the world`s second largest economy, is forecast to reach a projected market size of US$340.6 Million by the year 2030 trailing a CAGR of 5.9% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 5.7% and 5.1% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 5.1% CAGR.

Select Competitors (Total 42 Featured) -

  • Abbott Laboratories
  • CENETOGENE N.V.
  • GlaxoSmithKline
  • Johnson & Johnson
  • Novartis AG
  • Pfizer
  • Sanofi-Aventis SA
  • Shire
  • Teva Pharmaceutical Industries Ltd.
  • UCB Pharmaceuticals

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Krabbe Disease Treatment - Global Key Competitors Percentage Market Share in 2022 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E)
    • Impact of Covid-19 and a Looming Global Recession
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Krabbe Disease Treatment Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Krabbe Disease Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Krabbe Disease Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 4: World 16-Year Perspective for Krabbe Disease Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2014, 2023 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Anticonvulsants by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Anticonvulsants by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 7: World 16-Year Perspective for Anticonvulsants by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Muscle Relaxants by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Muscle Relaxants by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 10: World 16-Year Perspective for Muscle Relaxants by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Hematopoietic Stem Cell Transplantation (HSCT) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Hematopoietic Stem Cell Transplantation (HSCT) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 13: World 16-Year Perspective for Hematopoietic Stem Cell Transplantation (HSCT) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Other Therapies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Other Therapies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 16: World 16-Year Perspective for Other Therapies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Krabbe Disease Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2023 (E)
    • TABLE 17: USA Recent Past, Current & Future Analysis for Krabbe Disease Treatment by Therapy - Anticonvulsants, Muscle Relaxants, Hematopoietic Stem Cell Transplantation (HSCT) and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 18: USA Historic Review for Krabbe Disease Treatment by Therapy - Anticonvulsants, Muscle Relaxants, Hematopoietic Stem Cell Transplantation (HSCT) and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 19: USA 16-Year Perspective for Krabbe Disease Treatment by Therapy - Percentage Breakdown of Value Sales for Anticonvulsants, Muscle Relaxants, Hematopoietic Stem Cell Transplantation (HSCT) and Other Therapies for the Years 2014, 2023 & 2030
  • CANADA
    • TABLE 20: Canada Recent Past, Current & Future Analysis for Krabbe Disease Treatment by Therapy - Anticonvulsants, Muscle Relaxants, Hematopoietic Stem Cell Transplantation (HSCT) and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 21: Canada Historic Review for Krabbe Disease Treatment by Therapy - Anticonvulsants, Muscle Relaxants, Hematopoietic Stem Cell Transplantation (HSCT) and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 22: Canada 16-Year Perspective for Krabbe Disease Treatment by Therapy - Percentage Breakdown of Value Sales for Anticonvulsants, Muscle Relaxants, Hematopoietic Stem Cell Transplantation (HSCT) and Other Therapies for the Years 2014, 2023 & 2030
  • JAPAN
    • Krabbe Disease Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2023 (E)
    • TABLE 23: Japan Recent Past, Current & Future Analysis for Krabbe Disease Treatment by Therapy - Anticonvulsants, Muscle Relaxants, Hematopoietic Stem Cell Transplantation (HSCT) and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 24: Japan Historic Review for Krabbe Disease Treatment by Therapy - Anticonvulsants, Muscle Relaxants, Hematopoietic Stem Cell Transplantation (HSCT) and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 25: Japan 16-Year Perspective for Krabbe Disease Treatment by Therapy - Percentage Breakdown of Value Sales for Anticonvulsants, Muscle Relaxants, Hematopoietic Stem Cell Transplantation (HSCT) and Other Therapies for the Years 2014, 2023 & 2030
  • CHINA
    • Krabbe Disease Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2023 (E)
    • TABLE 26: China Recent Past, Current & Future Analysis for Krabbe Disease Treatment by Therapy - Anticonvulsants, Muscle Relaxants, Hematopoietic Stem Cell Transplantation (HSCT) and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 27: China Historic Review for Krabbe Disease Treatment by Therapy - Anticonvulsants, Muscle Relaxants, Hematopoietic Stem Cell Transplantation (HSCT) and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 28: China 16-Year Perspective for Krabbe Disease Treatment by Therapy - Percentage Breakdown of Value Sales for Anticonvulsants, Muscle Relaxants, Hematopoietic Stem Cell Transplantation (HSCT) and Other Therapies for the Years 2014, 2023 & 2030
  • EUROPE
    • Krabbe Disease Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2023 (E)
    • TABLE 29: Europe Recent Past, Current & Future Analysis for Krabbe Disease Treatment by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
    • TABLE 30: Europe Historic Review for Krabbe Disease Treatment by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 31: Europe 16-Year Perspective for Krabbe Disease Treatment by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2014, 2023 & 2030
    • TABLE 32: Europe Recent Past, Current & Future Analysis for Krabbe Disease Treatment by Therapy - Anticonvulsants, Muscle Relaxants, Hematopoietic Stem Cell Transplantation (HSCT) and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 33: Europe Historic Review for Krabbe Disease Treatment by Therapy - Anticonvulsants, Muscle Relaxants, Hematopoietic Stem Cell Transplantation (HSCT) and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 34: Europe 16-Year Perspective for Krabbe Disease Treatment by Therapy - Percentage Breakdown of Value Sales for Anticonvulsants, Muscle Relaxants, Hematopoietic Stem Cell Transplantation (HSCT) and Other Therapies for the Years 2014, 2023 & 2030
  • FRANCE
    • Krabbe Disease Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2023 (E)
    • TABLE 35: France Recent Past, Current & Future Analysis for Krabbe Disease Treatment by Therapy - Anticonvulsants, Muscle Relaxants, Hematopoietic Stem Cell Transplantation (HSCT) and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 36: France Historic Review for Krabbe Disease Treatment by Therapy - Anticonvulsants, Muscle Relaxants, Hematopoietic Stem Cell Transplantation (HSCT) and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 37: France 16-Year Perspective for Krabbe Disease Treatment by Therapy - Percentage Breakdown of Value Sales for Anticonvulsants, Muscle Relaxants, Hematopoietic Stem Cell Transplantation (HSCT) and Other Therapies for the Years 2014, 2023 & 2030
  • GERMANY
    • Krabbe Disease Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2023 (E)
    • TABLE 38: Germany Recent Past, Current & Future Analysis for Krabbe Disease Treatment by Therapy - Anticonvulsants, Muscle Relaxants, Hematopoietic Stem Cell Transplantation (HSCT) and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 39: Germany Historic Review for Krabbe Disease Treatment by Therapy - Anticonvulsants, Muscle Relaxants, Hematopoietic Stem Cell Transplantation (HSCT) and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 40: Germany 16-Year Perspective for Krabbe Disease Treatment by Therapy - Percentage Breakdown of Value Sales for Anticonvulsants, Muscle Relaxants, Hematopoietic Stem Cell Transplantation (HSCT) and Other Therapies for the Years 2014, 2023 & 2030
  • ITALY
    • TABLE 41: Italy Recent Past, Current & Future Analysis for Krabbe Disease Treatment by Therapy - Anticonvulsants, Muscle Relaxants, Hematopoietic Stem Cell Transplantation (HSCT) and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 42: Italy Historic Review for Krabbe Disease Treatment by Therapy - Anticonvulsants, Muscle Relaxants, Hematopoietic Stem Cell Transplantation (HSCT) and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 43: Italy 16-Year Perspective for Krabbe Disease Treatment by Therapy - Percentage Breakdown of Value Sales for Anticonvulsants, Muscle Relaxants, Hematopoietic Stem Cell Transplantation (HSCT) and Other Therapies for the Years 2014, 2023 & 2030
  • UNITED KINGDOM
    • Krabbe Disease Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2023 (E)
    • TABLE 44: UK Recent Past, Current & Future Analysis for Krabbe Disease Treatment by Therapy - Anticonvulsants, Muscle Relaxants, Hematopoietic Stem Cell Transplantation (HSCT) and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 45: UK Historic Review for Krabbe Disease Treatment by Therapy - Anticonvulsants, Muscle Relaxants, Hematopoietic Stem Cell Transplantation (HSCT) and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 46: UK 16-Year Perspective for Krabbe Disease Treatment by Therapy - Percentage Breakdown of Value Sales for Anticonvulsants, Muscle Relaxants, Hematopoietic Stem Cell Transplantation (HSCT) and Other Therapies for the Years 2014, 2023 & 2030
  • REST OF EUROPE
    • TABLE 47: Rest of Europe Recent Past, Current & Future Analysis for Krabbe Disease Treatment by Therapy - Anticonvulsants, Muscle Relaxants, Hematopoietic Stem Cell Transplantation (HSCT) and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 48: Rest of Europe Historic Review for Krabbe Disease Treatment by Therapy - Anticonvulsants, Muscle Relaxants, Hematopoietic Stem Cell Transplantation (HSCT) and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 49: Rest of Europe 16-Year Perspective for Krabbe Disease Treatment by Therapy - Percentage Breakdown of Value Sales for Anticonvulsants, Muscle Relaxants, Hematopoietic Stem Cell Transplantation (HSCT) and Other Therapies for the Years 2014, 2023 & 2030
  • ASIA-PACIFIC
    • Krabbe Disease Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2023 (E)
    • TABLE 50: Asia-Pacific Recent Past, Current & Future Analysis for Krabbe Disease Treatment by Therapy - Anticonvulsants, Muscle Relaxants, Hematopoietic Stem Cell Transplantation (HSCT) and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 51: Asia-Pacific Historic Review for Krabbe Disease Treatment by Therapy - Anticonvulsants, Muscle Relaxants, Hematopoietic Stem Cell Transplantation (HSCT) and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 52: Asia-Pacific 16-Year Perspective for Krabbe Disease Treatment by Therapy - Percentage Breakdown of Value Sales for Anticonvulsants, Muscle Relaxants, Hematopoietic Stem Cell Transplantation (HSCT) and Other Therapies for the Years 2014, 2023 & 2030
  • REST OF WORLD
    • TABLE 53: Rest of World Recent Past, Current & Future Analysis for Krabbe Disease Treatment by Therapy - Anticonvulsants, Muscle Relaxants, Hematopoietic Stem Cell Transplantation (HSCT) and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 54: Rest of World Historic Review for Krabbe Disease Treatment by Therapy - Anticonvulsants, Muscle Relaxants, Hematopoietic Stem Cell Transplantation (HSCT) and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 55: Rest of World 16-Year Perspective for Krabbe Disease Treatment by Therapy - Percentage Breakdown of Value Sales for Anticonvulsants, Muscle Relaxants, Hematopoietic Stem Cell Transplantation (HSCT) and Other Therapies for the Years 2014, 2023 & 2030

IV. COMPETITION